Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its participation in two major healthcare conferences this November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its participation in two major healthcare conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 13 at 3:00 p.m. ET in Boston, and at the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET in New York. Both presentations will feature management fireside chats and will be available via live webcast on the company's website, with recordings archived for up to 30 days.
Details
News Market Reaction – NMRA
The recorded move for NMRA in the trading session of this news was +6.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November:
- Guggenheim’s Inaugural Healthcare Innovation Conference: Members of management will participate in a fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.
- Stifel 2024 Healthcare Conference: Members of management will participate in a fireside chat on Monday, November 18, 2024, at 10:20 a.m. ET in New York, NY.
A live webcast of each event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcasts will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.